Brought to you by 
NeuroSearch grants Acesion Pharma rights to atrial fibrillation compounds
05 Nov 2018
Executive Summary
Concurrent with its spin off of Acesion Pharma APS, NeuroSearch AS has granted the new cardiovascular therapy company an option to license new and existing SK channel modulators that could be developed for atrial fibrillation (AF).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NeuroSearch grants Acesion Pharma rights to atrial fibrillation compounds
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice